In:
European Journal of Haematology, Wiley, Vol. 101, No. 4 ( 2018-10), p. 542-548
Abstract:
The aim of this study was to analyse the clinical characteristics and outcome of children diagnosed with Ph+ ALL . Material and Methods A total of 2591 newly diagnosed ALL children were treated in Poland between the years 2005 and 2017. Of those, 44 were diagnosed with Ph(+) ALL . The patients were treated according to protocols: ALL IC ‐ BFM 2002 and 2009 (26 patients), EsPh ALL (12 patients), initially ALL IC ‐ BFM and then EsPh ALL (6 patients). Results The median of follow‐up in the observed group was 3 years. Overall survival ( OS ) and event‐free survival ( EFS ) of Ph+ ALL group were 0.73 and 0.64. OS and EFS of patients after HSCT were 0.78 and 0.66, while without HSCT were 0.6 and 0.6, P = 0.27 and 0.63. OS was 0.8 for patients treated with chemotherapy plus imatinib and 0.61 for chemotherapy alone, P = 0.22, while EFS was 0.66 (imatinib therapy) and 0. 61 (without imatinib), P = 0.41. Conclusion Our study suggests that adding imatinib to intensive chemotherapy seems to improve outcome. However, this study was limited by a small number of patients and a variety of chemotherapy regimens with or without imatinib.
Type of Medium:
Online Resource
ISSN:
0902-4441
,
1600-0609
DOI:
10.1111/ejh.2018.101.issue-4
Language:
English
Publisher:
Wiley
Publication Date:
2018
detail.hit.zdb_id:
2027114-1
Bookmarklink